Hsbc Holdings PLC Grows Stake in Becton, Dickinson and Company $BDX

21 Jun 2026, 09:29 by Michael Walen · The Markets Daily

Hsbc Holdings PLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 53.7% in the fourth quarter, Holdings Channel reports. The fund owned 940,908 shares of the medical instruments supplier’s stock after acquiring an additional 328,717 shares during the quarter. Hsbc Holdings PLC’s holdings in Becton, Dickinson and Company were worth $183,161,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of BDX. Vanguard Group Inc. lifted its stake in Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after purchasing an additional 4,223,149 shares during the last quarter. State Street Corp increased its position in Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after buying an additional 116,737 shares during the last quarter. First Eagle Investment Management LLC raised its stake in shares of Becton, Dickinson and Company by 16.5% in the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after buying an additional 1,651,592 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Becton, Dickinson and Company by 3.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier’s stock valued at $1,841,083,000 after buying an additional 336,110 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Becton, Dickinson and Company by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier’s stock valued at $1,331,165,000 after buying an additional 53,884 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on BDX. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Argus lowered their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, March 23rd. Piper Sandler dropped their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Finally, TD Cowen cut their price objective on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday, May 4th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $181.00.

Read Our Latest Report on Becton, Dickinson and Company

Insider Transactions at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total transaction of $166,628.00. Following the completion of the transaction, the executive vice president owned 14,272 shares in the company, valued at approximately $2,161,922.56. This trade represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,013 shares of company stock worth $593,434 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $143.99 on Friday. The company’s 50 day simple moving average is $148.89 and its two-hundred day simple moving average is $172.31. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a market capitalization of $39.67 billion, a PE ratio of 36.45, a P/E/G ratio of 10.19 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same period in the previous year, the business earned $3.35 EPS. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.